Results 51 to 60 of about 114,000 (325)

Pericardial effusion caused by viral pericarditis in a patient receiving peritoneal dialysis

Renal Replacement Therapy, 2022
Background Acute pericarditis causes acute inflammation of the pericardium. Although most cases of pericarditis are idiopathic with no identifiable cause, its etiology can be infectious, such as viral, bacterial, mycotic, and tuberculous infections, or ...
Masahiro Egawa, Shungo Fujii, Kentaro Takase, Ryuichi Yoshimura, Asuka Yamauchi, Kaori Yoshikane, Kazuaki Tanabe, Hiroaki Shiina, Takafumi Ito   +8 more
doaj   +1 more source

Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis

BioDrugs, 2022
Although most patients with acute pericarditis will recover, a minority will have recurrent, debilitating episodes. In these patients, refractory symptoms result in high morbidity, and typically require a prolonged duration of anti-inflammatory treatment.
Bryan Q. Abadie, P. Cremer
semanticscholar   +1 more source

Three-year outcomes of a once daily fractionation scheme for accelerated partial breast irradiation (APBI) using 3-D conformal radiotherapy (3D-CRT). [PDF]

, 2013
The aim of this study was to report 3-year outcomes of toxicity, cosmesis, and local control using a once daily fractionation scheme (49.95 Gy in 3.33 Gy once daily fractions) for accelerated partial breast irradiation (APBI) using three-dimensional ...
Daroui, Parima, Goyal, Sharad, Haffty, Bruce G, Kearney, Thomas, Khan, Atif J, Kirstein, Laurie   +5 more
core   +2 more sources

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis

Current Cardiology Reports, 2022
Purpose of Review We reviewed the contemporary literature and clinical trials to discuss the applications of the interleukin-1 (IL-1) inhibitor rilonacept to treat pericarditis, with regards to pathophysiology, pharmacology, efficacy, and safety.
T. Wang, Allan L. Klein
semanticscholar   +1 more source

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial [PDF]

, 2018
BackgroundModified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
Chaplin, Paul, De Carli, Sonja, Kreusel, Christian, Lawrence, Steven J, Meyer, Thomas P, Nopora, Katrin, Overton, Edgar Turner, Rosch, Siegfried, Samy, Nathaly, Schnidt, Darja, Wagner, Eva, Weidenthaler, Heinz, Young, Philip   +12 more
core   +3 more sources

Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis

Frontiers in Medicine, 2022
The field of inflammatory disease of the heart or “cardio-immunology” is rapidly evolving due to the wider use of non-invasive diagnostic tools able to detect and monitor myocardial inflammation.
E. Ammirati, E. Bizzi, G. Veronese, M. Groh, C. M. Van de Heyning, J. Lehtonen, Marc Pineton de Chambrun, A. Cereda, C. Picchi, L. Trotta, J. Moslehi, A. Brucato   +11 more
semanticscholar   +1 more source

Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines

Pharmaceuticals, 2022
Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events ...
Concetta Rafaniello, Mario Gaio, Alessia Zinzi, Maria Giuseppa Sullo, Valerio Liguori, Marialuisa Ferraro, Fiorella Petronzelli, Patrizia Felicetti, Pasquale Marchione, Anna Rosa Marra, Francesco Rossi, Antonella De Angelis, Annalisa Capuano   +12 more
doaj   +1 more source

Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID‐19 patients

European Journal of Clinical Investigation, 2021
COVID‐19 has a wide spectrum of cardiovascular sequelae including myocarditis and pericarditis; however, the prevalence and clinical impact are unclear.
B. Buckley, S. Harrison, Elnara Fazio-Eynullayeva, P. Underhill, D. Lane, G. Lip   +5 more
semanticscholar   +1 more source

Outbreak of encephalitic listeriosis in red-legged partridges (Alectoris rufa) [PDF]

, 2015
An outbreak of neurological disease was investigated in red-legged partridges between 8 and 28 days of age. Clinical signs included torticollis, head tilt and incoordination and over an initial eight day period approximately 30–40 fatalities occurred per
Barnes H.J., Basher H.A., Fonnesbech Vogel B., Gitter M., Ivanics E., Lucas A., McDiarmid A., McKellar R.C., Okwumabua O.E., Paterson J.S., Paterson J.S., Seeliger H.P., Vaissaire J., Vijayakrishna S.   +13 more
core   +2 more sources

Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology ...
M. Imazio, A. Klein, A. Brucato, Antonio Abbate, M. Arad, Paul C. Cremer, Antonella Insalaco, Martin M LeWinter, Basil S Lewis, D. Lin, S. A. Luis, Stephen J. Nicholls, Paul Sutej, Y. Wasserstrum, J. Clair, Indra Agarwal, Sheldon Wang, J. Paolini   +17 more
semanticscholar   +1 more source